To inform the choice of systemic treatment for these patients, Ki-67 labeling index should be used in combination with other parameters, including tumor grade and a quantitative evaluation of ER and progesterone receptor (PgR) expression [3]. The gene discussed is PGR; the disease is neoplasm.